Figure 1a:
Overall survival of 110 patients with DLBCL after ASCT. Figure 1b: Survival of all patients who were rituximab naïve and rituximab exposed.
Overall survival of 110 patients with DLBCL after ASCT. Figure 1b: Survival of all patients who were rituximab naïve and rituximab exposed.